Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 4, 2010, Pages 523-533

  Hazazi, R ^a   Rozen, P ^a,c   Leshno, M ^c   Levi, Z ^a   Samuel, Z ^a   Waked, A ^a   Vilkin, A ^a   Maoz, E ^b   Birkenfeld, S ^b   Niv, Y ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PRIORITY JOURNAL;

ADENOMA; COLONOSCOPY; COLORECTAL NEOPLASMS; DISEASE SUSCEPTIBILITY; EPIDEMIOLOGIC METHODS; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD;

EID: 74049128844     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04202.x     Document Type: Article

References (22)

1. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006 56 : 143 159.
2. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol 2009 104 : 739 750.
3. Dove-Edwin I, Sasieni P, Adams J, Thomas HJW. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. Brit Med J 2005 331 : 1047 1052.
4. Rozen P, Levi Z, Hazazi R, et al. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical fecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009 29 : 450 457.
5. Caffarey SM, Broughton CI, Marks CG. Faecal occult blood screening for colorectal neoplasia in a targeted high-risk population. Br J Surg 1993 80 : 1399 1400.
6. Leiberman DA, Holub J, Eisen G, Kraemer D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005 62 : 875 883.
7. John DJB, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA. Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Intern Med 1992 117 : 376 382.
8. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood screening test for colorectal neoplasia. Ann Intern Med 2007 146 : 244 255.
9. Rozen P, Levi Z, Hazazi R, et al. Identification of colorectal adenomas by a quantitative immunochemical fecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009 29 : 906 917.
10. Bampton PA, Sandford JJ, Cole SR, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut 2005 54 : 803 806.
11. Levi Z, Rozen P, Hazazi R, et al. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer? Aliment Pharmacol Ther 2006 24 : 1475 1481.
12. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005 100 : 2519 2526.
13. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006 12 : MT27 32 http://www.MedSciMonit.com (accessed November 2009).
14. Levi Z, Rozen P, Hazazi R, et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009 104 : 933 938.
15. Schoenfeld PS, Fincher RK, for the Military Colorectal Cancer Screening Trials Group. Colonoscopic surveillance of patients with a family history of colon cancer and a history of normal colonoscopy: is a five-year interval between colonoscopies appropriate? Clin Gastroenterol Hepatol 2003 1 : 310 314.
16. Pabby A, Schoen RE, Weissfeld JL, et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 2005 61 : 385 391.
17. Robertson DJ, Greenberg ER, Beach M, et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 2005 129 : 34 41.
18. Farrar WD, Sawhney MS, Nelson DB, Lederle FA, Bond JH. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol 2006 4 : 1259 1264.
19. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 2007 132 : 96 102.
20. Boolchand V, Olds G, Singh J, Singh P, Chak A, Cooper GS. Colorectal screening after polypectomy: a national survey study of primary care physicians. Ann Intern Med 2006 145 : 654 659.
21. Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 2002 9 : 99 103.
22. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000 343 : 169 174.